Papp, K A <br/><br/>
Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.  [electronic resource] 

 -  The British journal of dermatology  Sep 2012 
 - 668-77 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1365-2133 
<br/><br/><label>Standard No.: </label>10.1111/j.1365-2133.2012.11168.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adult<br/>Chronic Disease<br/>Dermatologic Agents--administration & dosage<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Female<br/>Humans<br/>Janus Kinase 3--antagonists & inhibitors<br/>Male<br/>Piperidines<br/>Psoriasis--drug therapy<br/>Pyrimidines--administration & dosage<br/>Pyrroles--administration & dosage<br/>Treatment Outcome